Yuan Zhi
Stock Analyst at B. Riley Securities
(0.18)
# 4,021
Out of 4,818 analysts
22
Total ratings
14.29%
Success rate
-34.86%
Average return
Main Sectors:
Stocks Rated by Yuan Zhi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIR Mirion Technologies | Maintains: Buy | $19 → $17 | $14.28 | +19.05% | 2 | Apr 16, 2025 | |
| HYPR Hyperfine | Maintains: Buy | $1.5 → $1.2 | $0.77 | +55.84% | 1 | Mar 20, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $15 | $4.15 | +261.45% | 1 | Mar 12, 2025 | |
| TNGX Tango Therapeutics | Maintains: Buy | $16 → $8 | $1.49 | +436.91% | 2 | Nov 11, 2024 | |
| AGEN Agenus | Maintains: Buy | $42 → $18 | $2.85 | +531.58% | 2 | Aug 14, 2024 | |
| CYRX Cryoport | Upgrades: Buy | $19 → $15 | $5.60 | +168.10% | 4 | Jul 31, 2024 | |
| CTSO Cytosorbents | Reiterates: Buy | $3 | $1.07 | +180.37% | 1 | May 15, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $12 → $17 | $2.34 | +626.50% | 2 | Apr 9, 2024 | |
| AZTA Azenta | Maintains: Buy | $61 → $79 | $25.77 | +206.56% | 3 | Feb 1, 2024 | |
| ATNM Actinium Pharmaceuticals | Maintains: Buy | $20 → $16 | $1.29 | +1,140.31% | 4 | Dec 11, 2023 |
Mirion Technologies
Apr 16, 2025
Maintains: Buy
Price Target: $19 → $17
Current: $14.28
Upside: +19.05%
Hyperfine
Mar 20, 2025
Maintains: Buy
Price Target: $1.5 → $1.2
Current: $0.77
Upside: +55.84%
Radiopharm Theranostics
Mar 12, 2025
Initiates: Buy
Price Target: $15
Current: $4.15
Upside: +261.45%
Tango Therapeutics
Nov 11, 2024
Maintains: Buy
Price Target: $16 → $8
Current: $1.49
Upside: +436.91%
Agenus
Aug 14, 2024
Maintains: Buy
Price Target: $42 → $18
Current: $2.85
Upside: +531.58%
Cryoport
Jul 31, 2024
Upgrades: Buy
Price Target: $19 → $15
Current: $5.60
Upside: +168.10%
Cytosorbents
May 15, 2024
Reiterates: Buy
Price Target: $3
Current: $1.07
Upside: +180.37%
Perspective Therapeutics
Apr 9, 2024
Maintains: Buy
Price Target: $12 → $17
Current: $2.34
Upside: +626.50%
Azenta
Feb 1, 2024
Maintains: Buy
Price Target: $61 → $79
Current: $25.77
Upside: +206.56%
Actinium Pharmaceuticals
Dec 11, 2023
Maintains: Buy
Price Target: $20 → $16
Current: $1.29
Upside: +1,140.31%